APR Applied Pharma Research
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ch 5, Balerna, Ticino, 6828, SwitzerlandPhone Number
+41 916957020Website
www.apr.chRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About APR Applied Pharma Research
APR Applied Pharma Research is a Swiss pharmaceutical company specializing in the development and commercialization of innovative products for rare and ultra-rare diseases. The company offers a range of prescription and consumer healthcare products, including solutions for metabolic disorders, wound care, and cancer supportive care. APR also provides contract research and development services to the pharmaceutical industry, leveraging advanced drug delivery technologies. Their target clients include patients with rare diseases and healthcare providers seeking effective treatment options.Explore more
APR Applied Pharma Research Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is APR Applied Pharma Research your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when APR Applied Pharma Research launches new products
Check out if APR Applied Pharma Research is spiking on competitors!
APR Applied Pharma Research, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if APR Applied Pharma Research had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at APR Applied Pharma Research
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if APR Applied Pharma Research has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once APR Applied Pharma Research has new funding data
Earning: See what the market has to say on APR Applied Pharma Research recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
APR Applied Pharma Research is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
APR Applied Pharma Research is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about APR Applied Pharma Research.
APR Applied Pharma Research Tech Stack
A closer look at the technologies used by APR Applied Pharma Research
APR Applied Pharma Research News & Media
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare...Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
(" Meta "), acquiring the worldwide rights, except for the United Kingdom (" UK "), for a novel dosage form of a prescription drug already approved by the U. Food and Drug Administration (" FDA ") and intended for the treatment of patients with phenylketonuria (" PKU ").Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U. until 2039GENEVA, SWITZERLAND / ACCESSWIRE / January 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA ("APR"), has reRelief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
Relief also reported that data from the study suggest that Sentinox could be effective in reducing the SARS-CoV-2 viral load at the level of the nasal mucosa.The post-market, confirmatory, interventional, randomized, placebo controlled clinical study is expected to enroll a total of 57 patients.
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding APR Applied Pharma Research
Sign Up For FreeTo access detailed company insights
APR Applied Pharma Research is a Swiss pharmaceutical company specializing in the development and commercialization of innovative products for rare and ultra-rare diseases. The company offers a range of prescription and consumer healthcare products, including solutions for metabolic disorders, wound care, and cancer supportive care. APR also provid... Read More
